Martha Sajatovic, MD
Associate Professor Department of Psychiatry
Case Western Reserve University School of Medicine
William Glazer, MD
Associate Clinical Professor of Psychiatry
Harvard Medical School
President, Glazer Medical Solutions
This is the second program in a two-part series based on live audioconference presentations.
Appropriate therapeutic management of bipolar disorder (BPD) is critical for effective outcomes. Mismanaged patients experience poor quality of life and comparatively high medical costs (direct and indirect). These patients also typically have many comorbidities (psychological and somatic), often with attendant polypharmacy. Recognizing specific symptoms and carefully individualizing therapy may have a significantly positive impact on patients with BPD. Patient adherence to therapy and physician compliance with guidelines and recommendations also contribute significantly to patient outcomes. Effective management of the disorder requires careful synthesis and consideration of the "complete patient" for optimal outcomes with minimized costs. This online "virtual meeting" provides strategies for cost-effective therapeutic options to manage patients with BPD. Program Developer/Facilitator
. Target Audience
Managed Care Medical Directors, Pharmacy Directors, Physicians, and Pharmacists.
Upon completion of this educational activity, the participant should be able to:
Identify the most frequent disease states comorbid with bipolar disorder
Evaluate strategies to better enable treatment providers (such as PCPs and psychiatrists) to enhance adherence and overall care of patients with bipolar disorder in managed care settings
Recognize the importance of treating bipolar disorder with its comorbidities
Discuss current and potential indications for pharmacotherapy for bipolar disorder
AKH Inc. and its shareholders have no significant financial relationships with the manufacturers of medical or pharmaceutical products, nor with the providers of non-educational medical services. It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with the commercial companies whose products or devices may be mentioned in the monograph or with the commercial supporter of this continuing education activity. The information is for participant information only; it is not assumed that these relationships will have a negative impact on the content of the activity.
Martha Sajatovic, MD discloses that she is on speakers bureaus of AstraZeneca, GlaxoSmithKline, and Pfizer Inc, is a consultant for AstraZeneca and GlaxoSmithKline, serves on advisory committees for Bristol-Myers Squibb Company and AstraZeneca, and has received research support from Bristol-Myers Squibb Company and Abbott Laboratories.
William M. Glazer, MD discloses that he is on advisory committees of Eli Lilly and Company, AstraZeneca, Abbott Laboratories and Pfizer Inc. He is also president of ReliaLAB Inc.
This educational activity may contain discussion of published and/or investigational uses of agents for the treatment of bipolar disorder. Some uses of these agents have not been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
CME: This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
CPE: AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been assigned the Universal Program Number 077-999-06-001-H04 and is acceptable for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE-approved providers.
Participants must submit an evaluation and complete a post-test with a score of 70% or better to receive credit. Commercial Support Statements
This activity is supported by an educational grant from AstraZeneca.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program.
Clicking on "start the program" on this screen will bring you to instructions to turn off pop-up blockers and allow you to begin the program presentation which will take approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to register and access the post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE certificate.
None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.